Gemina Laboratories Ltd. (CSE:GLAB)
Canada · Delayed Price · Currency is CAD 0.7500
+0.0700 (10.29%)
Jul 30, 2025, 3:56 PM EDT
Gemina Laboratories Company Description
Gemina Laboratories Ltd., a biotechnology company, engages in the research, development, and commercialization of in-vitro diagnostics in Canada.
The company's products include LEGIO X COVID-19, a COVID-19 rapid antigen test; and LEGIO X Influenza AB, an influenza AB multiplex lateral flow test.
It also develops respiratory syncytial virus and tuberculosis. Gemina Laboratories Ltd. was incorporated in 2017 and is headquartered in Burnaby, Canada.
Gemina Laboratories Ltd.
| Country | Canada |
| Founded | 2017 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 6 |
| CEO | Brian Firth |
Contact Details
Address: 3600 Gilmore Way Burnaby, British Columbia V5G 4W8 Canada | |
| Website | geminalabs.com |
Stock Details
| Ticker Symbol | GLAB |
| Exchange | Canadian Securities Exchange |
| Fiscal Year | February - January |
| Reporting Currency | CAD |
| ISIN Number | CA3686501071 |
| SIC Code | 6722 |
Key Executives
| Name | Position |
|---|---|
| Brian Firth | Chief Executive Officer and Director |
| Michael Liggett B.Sc., Bsc. Pharm., C.A., C.P.A., CA, CPA | Chief Financial Officer and Company Secretary |
| Dr. Robert Crandall Greene | Chief Technology Officer and Director |
| Hugh McNaught | Vice President of Marketing and Member of Advisory Board |
| David Browning FCIM, M.Sc. | Head of Productization and Director of Gemina Laboratories (UK) Limited |
| Dr. Christine Buerki Ph.D. | Head of Product Development |